IONS — Ionis Pharmaceuticals Inc. stock price and chart

Share this page

IONS

$42.94-2.67%

as of close, Oct 16, 2026

☾ AH $42.94 -2.67%

Ionis Pharmaceuticals Inc.Stock · HealthcareNasdaq Composite 0.03%Russell 1000 0.02%Russell 3000 0.02%US Stock Market 0.02%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEE

20162019202120242026

30.040.050.060.070.080.0020.0M40.0M$42.94

2026-10-16

Price$42.94

MA20$62.45

MA50$68.60

Vol16.0M

What would $1,000 invested in IONS be worth today? →

IONS returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $42.94
YTD price return: -45.72%
YTD total return: -45.72%
Next earnings: Nov 4, 2026
Market cap: 7.1B2016-12 5.8B2026-10 7.1B+23.2% over the window
Enterprise value: 6.7B
Shares outstanding: 166.2M2016-06 120.9M2026-06 166.2M+37.4% over the window
52W low: $42.08
52W high: $86.74
From 52W high: -50.50%
From 52W low: +2.04%
52W range: 2%

Volume

Rel volume: 0.42×
30D volume: 4M
30D $ vol: 186.7M

Fundamentals

Sales (ttm): 874.1M2016-06 176M2026-06 874.1M+396.5% over the window
Sales/share: $5.262016-06 $1.462026-06 $5.26+261.3% over the window
EPS (ttm): -$3.462016-06 -$1.882026-06 -$3.46+84.0% over the window
FCF (ttm): -560.8M2016-06 -117.8M2026-06 -560.8M+376.0% over the window
FCF/share: -$3.372016-06 -$0.972026-06 -$3.37+246.3% over the window
Book value/share: $2.652016-06 $0.922026-06 $2.65+187.7% over the window
Net margin: -64.66%2016-06 -128.9%2026-06 -64.7%-49.9% over the window
ROE: -128.53%2016-06 -204.1%2026-06 -128.5%-37.0% over the window
ROA: -18.87%2016-06 -28.0%2026-06 -18.9%-32.6% over the window
Debt / equity: 3.02×2019-12 0.532025-12 2.72+408.5% over the window
Current ratio: 7.892016-06 6.282026-06 7.89+25.6% over the window

Growth (CAGR, ttm) · 10Y

Sales: -7.42%2025-06-30 → 2026-06-30944.1M → 874.1M (-7.4% total)+11.50%2023-06-30 → 2026-06-30630.6M → 874.1M (+38.6% total)+4.91%2021-06-30 → 2026-06-30687.7M → 874.1M (+27.1% total)+17.38%2016-06-30 → 2026-06-30176M → 874.1M (+396.5% total)
Shares: +4.26%2025-06-30 → 2026-06-30159.4M → 166.2M (+4.3% total)+5.05%2023-06-30 → 2026-06-30143.3M → 166.2M (+15.9% total)+3.32%2021-06-30 → 2026-06-30141.1M → 166.2M (+17.7% total)+3.23%2016-06-30 → 2026-06-30120.9M → 166.2M (+37.4% total)

Per-share growth (CAGR, ttm) · 10Y

Sales/share: -11.20%2025-06-30 → 2026-06-30$5.92 → $5.26 (-11.2% total)+6.13%2023-06-30 → 2026-06-30$4.40 → $5.26 (+19.5% total)+1.54%2021-06-30 → 2026-06-30$4.87 → $5.26 (+8.0% total)+13.71%2016-06-30 → 2026-06-30$1.46 → $5.26 (+261.3% total)
Book value/share: -33.25%2025-06-30 → 2026-06-30$3.96 → $2.65 (-33.2% total)-3.97%2023-06-30 → 2026-06-30$2.99 → $2.65 (-11.5% total)-8.51%2021-06-30 → 2026-06-30$4.13 → $2.65 (-35.9% total)+11.15%2016-06-30 → 2026-06-30$0.92 → $2.65 (+187.7% total)
Price: -41.26%2025-10-16 → 2026-10-16$73.07 → $42.94 (-41.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-3.74%2023-10-16 → 2026-10-16$48.14 → $42.94 (-10.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+4.11%2021-10-15 → 2026-10-16$35.10 → $42.94 (+22.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+4.00%2016-10-14 → 2026-10-16$29.00 → $42.94 (+48.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: -41.26%2025-10-16 → 2026-10-16$73.07 → $42.94 (-41.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-3.74%2023-10-16 → 2026-10-16$48.14 → $42.94 (-10.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+4.11%2021-10-15 → 2026-10-16$35.10 → $42.94 (+22.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+4.00%2016-10-14 → 2026-10-16$29.00 → $42.94 (+48.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: -12.4×2016-12 -31.532026-10 -12.63-59.9% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 291.1×2016-12 -38.542026-10 -12.01-68.8% over the window
Fwd P/E: -40.9×
P/S (ttm)Market cap ÷ TTM revenue.: 8.2×2016-12 24.372026-10 8.17-66.5% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 16.2×2016-12 41.522026-10 16.24-60.9% over the window
EV/Sales (ttm): 7.6×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: -7.86%2016-09 -2.2%2026-06 -4.3%+90.6% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 166.2M ÷ 159.4M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -4.26%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-4.26%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($6.3B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -4.26%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($7.1B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2016-09 0.0%2026-06 0.0%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($7.1B). Same caveat as the cash buyback yield.: 0.00%2016-09 0.0%2026-06 0.0%

Vs own 10Y history

P/E: 84th
P/OI: 79th
P/S: 36th
P/B: 63rd
P/FCF: 41st

Bar = where today’s multiple sits in IONS’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-2.67%

-5.17%

-4.24%

-21.43%

YTD

-45.72%

-41.23%

+22.34%

Financial statements

Open full IONS financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

IONS — Ionis Pharmaceuticals Inc. price, chart and key statistics